Navigation Links
Shengtai Pharmaceutical Expands International Sales Program
Date:10/30/2008

- Dedicated Sales Team Focused on Key Global Markets -

WEIFANG, Shandong, China, Oct. 30 /Xinhua-PRNewswire-FirstCall/ -- Shengtai Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) ("Shengtai" or "the Company"), a leading manufacturer and distributor of high-quality, pharmaceutical grade glucose products in China, today announced that it has restructured its international sales team committed to broaden Shengtai's product sales into selected global markets.

The international sales team is an integral part of our existing sales department as the Company sees growth potential in the overseas markets. Currently, the Company has existing customers in over 70 countries. The new team assumes responsibilities of all aspects of the international sales include research, regulatory affairs, marketing and sales to ensure the successful introduction of the Company's health and other products into targeted international markets. Shengtai's pharmaceutical grade glucose products have wide application in hospitals, clinics and other health-related services.

Recently, the international sales team attended the Guangzhou International Fair and presented Shengtai's products. The response from potential customers at this conference was encouraging.

Shengtai recently received the "Good Manufacturing Practice" (GMP) certificate for its new glucose manufacturing facility. This new facility has an annual production capacity of 120,000 tons and when combined with the existing plant provides the Company with a total annual capacity up to 180,000 tons of glucose. The Company is commencing operations in stages and will gradually ramp up production to expand its offerings.

Mr. Qingtai Liu, Chairman and CEO of Shengtai Pharmaceutical, stated, "Our high-quality products combined with low-cost, state-of-the-art manufacturing provides competitive advantages. We believe these advantages and our new production capacity will allow us to increase exports in targeted international markets."

"The Chinese market continues to represent a good growth opportunity for us as the economy is growing at approximately 8% in 2008. Additionally, the Chinese government is implementing policies to enhance economic growth through revised banking regulations to aid smaller businesses and effect reforms in rural areas to increase personal wealth, " Mr. Liu concluded.

About Shengtai Pharmaceutical, Inc.

Shengtai Pharmaceutical, Inc. through its wholly-owned subsidiary Shengtai Holding, Inc. (SHI), a New Jersey corporation, and the Chinese operating company of Weifang Shengtai Pharmaceutical Co., Ltd., is a leading manufacturer and supplier of pharmaceutical grade glucose used for medical purposes, and the glucose and cornstarch products for the food and beverage industry and for industrial production in China. For more information about Shengtai Pharmaceutical, Inc., please visit http://www.shengtaipharmaceutical.com .

Safe Harbor Statement

Certain statements in this press release and oral statements made by the Company constitute forward-looking statements. These statements include, without limitation, statements regarding our ability to prepare the company for growth, the Company's planned capacity expansion in 2008 and predictions and guidance relating to the Company's future financial performance. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs but they involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as unanticipated changes in product demand especially in the pharmaceutical industry, pricing and demand trends for the Company's products, changes to government regulations, risk associated with operation of the Company's new facilities, risk associated with large scale implementation of the company's business plan, the ability to attract new customers, ability to increase its product's applications, cost of raw materials, downturns in the Chinese economy, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. Investors are urged to consider these factors carefully in evaluating the forward-looking statements herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

For more information, please contact:

Shengtai Pharmaceutical, Inc.

Ms. Yiru Melody Shi

Chief Financial Officer

Tel: +1-949-468-7078

Email: shengtaicfo@hotmail.com

Grayling Global

Eddie Cheung

Investor Relations

Tel: +1-646-284-9414

Email: echeung@hfgcg.com


'/>"/>
SOURCE Shengtai Pharmaceutical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008
2. Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Third Quarter Results of Fiscal Year 2008
3. Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008
4. Shengtai Pharmaceutical, Inc. to Present at Roth Conference
5. Shengtai Pharmaceutical, Inc. to Present at Roth Capital Phoenix Conference
6. Shengtai Pharmaceutical, Inc. Reports First Quarter Results of Fiscal Year 2008
7. Shengtai Pharmaceutical, Inc. Reports Record 2007 Annual Results
8. MiddleBrook Pharmaceuticals Schedules Conference Call and Webcast for Third Quarter 2008 Financial Results
9. The Quigley Corporation Reports Third Quarter 2008 Results; Continues Investment in Pharmaceutical R&D Future
10. ISTA Pharmaceuticals Reports Third Quarter 2008 Financial Results
11. ADVENTRX Pharmaceuticals to Report Third Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to ... of individuals in the United States and Canada wear eyeglasses. Once considered to be ... vision and make a fashion statement. Even celebrities use glasses as a way of ...
(Date:6/26/2016)... ... ... blind and certified personal trainer is helping to develop a weight loss fitness plan that ... the two major problems leading the fitness industry today:, , All ... They don’t eliminate all the reasons people quit their exercise program , ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... and Markets has announced the addition of the ... their offering. ... products and provides an updated review, including its applications ... covering the total market, which includes three main industries: ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
(Date:6/24/2016)... , June 24, 2016  American Respiratory Labs (ARL), a ... now able to perform sophisticated lung assessments in patients, homes, thanks ... Inc. Patients are no longer limited to having ... PRO ® , ARL patients like Jeanne R. of ... the comfort of her own home. ...
Breaking Medicine Technology: